HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy
Conclusions HBV RNA showed distinct and corresponding profiles in patients with HBV in
different disease phases. HBV RNA and HBcrAg could be used to monitor residual …
different disease phases. HBV RNA and HBcrAg could be used to monitor residual …
A systematic review of direct acting antiviral therapies in hepatitis C virus‐negative liver transplant recipients of hepatitis C‐viremic donors
HS Snyder, JJ Wiegel, K Khalil… - … : The Journal of …, 2022 - Wiley Online Library
The introduction of safe and highly effective direct acting antivirals (DAAs) has significantly
improved hepatitis C virus (HCV) treatment outcomes after transplant. The solid organ …
improved hepatitis C virus (HCV) treatment outcomes after transplant. The solid organ …
Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
P Czarnecka, K Czarnecka, O Tronina… - Renal …, 2022 - Taylor & Francis
Kidney transplantation is the treatment of choice in end-stage renal disease. The main issue
which does not allow to utilize it fully is the number of organs available for transplant …
which does not allow to utilize it fully is the number of organs available for transplant …
Prospective multicenter study of early antiviral therapy in liver and kidney transplant recipients of HCV‐viremic donors
Background and Aims Organs from hepatitis C virus (HCV)‐viremic donors have been used
in HCV‐uninfected recipients (D+/R‐), but the optimal treatment approach has not been …
in HCV‐uninfected recipients (D+/R‐), but the optimal treatment approach has not been …
Liver transplantation of HCV-viremic donors into HCV-negative recipients in the United States: increasing frequency with profound geographic variation
Background. Direct-acting antiviral therapy made possible the novel practice of utilizing
hepatitis C virus (HCV)-viremic (HCV RNA-positive) donors into HCV-negative recipients in …
hepatitis C virus (HCV)-viremic (HCV RNA-positive) donors into HCV-negative recipients in …
[HTML][HTML] Outcomes of hepatitis C virus seropositive donors to hepatitis C virus seronegative liver recipients: a large single center analysis
LA Sobotka, K Mumtaz, MR Wellner, SG Kelly… - Annals of hepatology, 2021 - Elsevier
Introduction and objectives The success of direct-acting antivirals (DAA) has transformed the
management of hepatitis C virus (HCV) infection and has led to the expansion of the …
management of hepatitis C virus (HCV) infection and has led to the expansion of the …
Varying utilization rates but superior outcomes in liver transplantation from hepatitis C− positive donors in the United States: An analysis of the OPTN/UNOS database
Y Bekki, JF Crismale, B Myers, TD Schiano… - …, 2022 - journals.lww.com
Background. Liver transplantation (LT) from hepatitis C virus (HCV)− positive donors
[antibody positive (Ab+) or nucleic acid test− positive (NAT+) donors] has been reported to …
[antibody positive (Ab+) or nucleic acid test− positive (NAT+) donors] has been reported to …
Systematic review: hepatitis C viraemic allografts to hepatitis C‐negative recipients in solid organ transplantation
T Raasikh, T Jamali, A Flores, RT Cotton… - Alimentary …, 2021 - Wiley Online Library
Background Given the success of direct‐acting antivirals (DAAs) in treating hepatitis C
(HCV), interest is growing in utilizing solid organs from allografts with active HCV to expand …
(HCV), interest is growing in utilizing solid organs from allografts with active HCV to expand …
Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct‐acting antiviral initiation
MR Hudson, AR Webb, AT Logan… - Clinical …, 2021 - Wiley Online Library
The use of allografts from hepatitis C virus (HCV) Nucleic Acid Testing (NAT)+ donors into
HCV NAT‐recipients has been reported to be efficacious in a handful of studies. However …
HCV NAT‐recipients has been reported to be efficacious in a handful of studies. However …
[HTML][HTML] Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients
C Logan, I Yumul, J Cepeda, V Pretorius… - American Journal of …, 2021 - Elsevier
Outcomes following hepatitis C virus (HCV)-viremic heart transplantation into HCV-negative
recipients with HCV treatment are good. We assessed cost-effectiveness between cohorts of …
recipients with HCV treatment are good. We assessed cost-effectiveness between cohorts of …